Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00501826
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • T Acute Lymphoblastic Leukemia
  • T Lymphoblastic Lymphoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cyclophosphamide — DRUG
    Given IV
  • Cytarabine — DRUG
    Given IV
  • Dexamethasone — DRUG
    Given IV or PO
  • Doxorubicin Hydrochloride — DRUG
    Given IV
  • Mercaptopurine — DRUG
    Given PO
  • Methotrexate — DRUG
    Given IV and PO
  • Nelarabine — DRUG
    Given IV
  • Pegaspargase — DRUG
    Given IV
  • Prednisone — DRUG
    Given PO
  • Venetoclax — DRUG
    Given PO
  • Vincristine Sulfate — DRUG
    Given IV

Study Details

This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Key Dates

Start date
Jul 11, 2007
Status verified
Jan 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
160 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (nelarabine and combination chemotherapy)
    See Detailed Description

Primary Outcome Measure

Complete remission rate [ Time Frame: 3 years ]

Central Contacts

  • Farhad Ravandi-Kashani, MD
    713-745-0394

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030
Farhad Ravandi-Kashani
713-745-0394
Farhad Ravandi-Kashani (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
M D Anderson Cancer Center· Houston, TX

Related Studies